Publication:
Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.

dc.contributor.authorSepúlveda, Maria
dc.contributor.authorSola-Valls, Nuria
dc.contributor.authorEscudero, Domingo
dc.contributor.authorRojc, Bojan
dc.contributor.authorBarón, Manuel
dc.contributor.authorHernández-Echebarría, Luis
dc.contributor.authorGómez, Begoña
dc.contributor.authorDalmau, Josep
dc.contributor.authorSaiz, Albert
dc.contributor.authorGraus, Francesc
dc.date.accessioned2023-01-25T09:52:15Z
dc.date.available2023-01-25T09:52:15Z
dc.date.issued2017-09-18
dc.description.abstractIn a minority of patients with neuromyelitis optica spectrum disorder (NMOSD) and aquaporin-4 antibodies (AQP4-IgG), the disease has a paraneoplastic origin. It is unknown whether these patients have distinctive clinical features. To report the clinical features of a series of patients with paraneoplastic NMOSD and AQP4-IgG and to review previously reported cases. Retrospective analysis of clinical records of 156 patients with NMOSD and AQP4-IgG and review of previously reported patients with paraneoplastic NMOSD and AQP4-IgG. Paraneoplastic patients were defined as those with cancer identified within 2 years of the diagnosis of NMOSD. Five (3.2%) of 156 patients had paraneoplastic NMOSD, and 12 previously reported patients were identified. The most common tumors were adenocarcinoma of the lung (five patients) and breast (five). Compared with the 151 non-paraneoplastic NMOSD patients, the 17 (5 current cases and 12 previously reported) were older at symptom onset (median age = 55 (range: 17-87) vs 40 (range: 10-77) years; p = 0.006), more frequently male (29.4% vs 6.6%; p = 0.009), and presented with severe nausea and vomiting (41.2% vs 6.6%; p Patients, predominantly male, with NMOSD and AQP4-IgG should be investigated for an underlying cancer if they present with nausea and vomiting, or LETM after 45 years of age.
dc.identifier.doi10.1177/1352458517731914
dc.identifier.essn1477-0970
dc.identifier.pmcPMC5832634
dc.identifier.pmid28920766
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832634/pdf
dc.identifier.unpaywallURLhttps://europepmc.org/articles/pmc5832634?pdf=render
dc.identifier.urihttp://hdl.handle.net/10668/11586
dc.issue.number13
dc.journal.titleMultiple sclerosis (Houndmills, Basingstoke, England)
dc.journal.titleabbreviationMult Scler
dc.language.isoen
dc.organizationHospital Universitario de Puerto Real
dc.page.number1753-1759
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, N.I.H., Extramural
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectAQP4 antibodies
dc.subjectNeuromyelitis optica spectrum disorders
dc.subjectcancer
dc.subjectparaneoplastic
dc.subject.meshAdenocarcinoma
dc.subject.meshAged
dc.subject.meshAquaporin 4
dc.subject.meshAutoantibodies
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMyelitis, Transverse
dc.subject.meshNeuromyelitis Optica
dc.subject.meshRetrospective Studies
dc.titleClinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
dc.typeresearch article
dc.type.hasVersionAM
dc.volume.number24
dspace.entity.typePublication

Files